| 4.835 0.005 (0.1%) | 01-26 13:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.07 | 1-year : | 7.09 |
| Resists | First : | 5.19 | Second : | 6.07 |
| Pivot price | 4.63  |
|||
| Supports | First : | 4.41 | Second : | 3.93 |
| MAs | MA(5) : | 4.8 |
MA(20) : | 4.51 |
| MA(100) : | 4.24 |
MA(250) : | 3.35 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.1  |
D(3) : | 77 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 6.55 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SANA ] has closed below upper band by 26.5%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.12 - 5.15 | 5.15 - 5.17 |
| Low: | 4.77 - 4.79 | 4.79 - 4.81 |
| Close: | 4.79 - 4.83 | 4.83 - 4.87 |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Sun, 25 Jan 2026
Sana Biotechnology, Inc. $SANA Position Boosted by Baillie Gifford & Co. - MarketBeat
Fri, 23 Jan 2026
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet - Finviz
Mon, 19 Jan 2026
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips (NASDAQ:SANA) - Seeking Alpha
Thu, 08 Jan 2026
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - Yahoo Finance
Wed, 07 Jan 2026
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Sun, 30 Nov 2025
Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 266 (M) |
| Shares Float | 177 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 79.5 (%) |
| Shares Short | 36,620 (K) |
| Shares Short P.Month | 38,340 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.9 % |
| Return on Equity (ttm) | -96.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -5.04 |
| PEG Ratio | 0 |
| Price to Book value | 6.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|